Drug Trial Radar · NCT00592163
Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Planned (sponsor's estimate)
Start
Dec 2007
Primary completion
Jan 4, 2009
Study completion Jan 4, 2010
Sponsor
- Lead sponsor
- Alaunos TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jan 11, 2008
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I Study of Oral ZIO-101-C in Advanced Solid Tumors and Lymphomas
Conditions
- Advanced Solid Tumors
- Lymphomas
Interventions
ZIO-101-C (Darinaparsin)Drug
Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (\>8 hours between doses) for 3 weeks followed by 1 week of rest
Primary outcomes
What the sponsor says the trial is designed to measure.
- toxicitiesTime frame: 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Site not named
Montreal, Quebec, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.